A pharmaceutical composition comprising a co-crystal of a co-crystal forming compound and API, to be able at crystallization conditions, the co-crystal forming compound and the API co-crystallized from a liquid phase, wherein the API, ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine , secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s- heterocyclic ring, thiophene, n- heterocyclic ring, pyrrole, o- heterocyclic The co-crystal forming compound and having at least one functional group selected furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine, amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, A pharmaceutical composition comprising at least one functional group selected from methylthio carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and.
展开▼